Citations

Clear

2303 citation(s) found for "Yu, Edward".

Stability of Barium Sulfate Turbidity Standards
Washington, John A., Warren, Edward, Karlson, Alfred G., Warren, Edward

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 24 | Issue: 6 | Pages: 1013-1013

10.1128/am.24.6.1013-1013.1972 | PMID 4650595 Get It

McFarland barium sulfate standards prepared in 1952 were compared spectrophotometrically with freshly and identically prepared standards; the results were nearly identical.
TMOD-36. THE DEVELOPMENT OF A NOVEL MOUSE MODEL TO STUDY THE ROLE OF HISTONE MUTATIONS AND MODIFICATIONS IN PEDIATRIC HIGH-GRADE GLIOMA
Grigore, Florina , Hanson, Nicholas D., Langfald, Alyssa, Day, Charles , Sarkaria, Jann N. , Daniels, David J. , Hinchcliffe, Edward H. , Robinson, James

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii235-ii235

10.1093/neuonc/noaa215.986 Get It

Abstract Pediatric glioblastoma and diffuse intrinsic pontine glioma are high-grade gliomas of children (pHGG) with a median overall survival of under 15 months and among the most lethal cancers. Mutations in histone H3.3 and H3.1 occur as an early event in pHGG. H3.3G34R/V-mutations occur in pHGG of cerebral hemispheres, and H3.3K27M mutations occur in midline pHGGs. Post-translational histone modifications (PTMs) serve to regulate gene expression by relaxing or compacting chromatin and by recruiting proteins, with subsequent silencing or activating effects. H3.3 Serine 31 (S31) shows reduced phosphorylation during mitosis in H3.3G34R/V and H3.3K27M mutant cell. Phosphorylation at S31 is restored in wildtype H3.3K27 CRISPR revertants. Serine to alanine (A) mutant H3.3 S31A are nonphosphorylatable in vitro. To study the influence of histone mutations and the role of altered PTM and including the loss of methylation and phosphorylation on tumorigenesis, we have developed an innovative model based on the RCAS/N-TVA mouse model. In this system, the expression of an oncogenic driver is linked to mutant histone expression using a self-cleaving peptide, and tumors develop following viral delivery to neural stem cells in newborn mice. This approach is necessary, as otherwise, clonal selection could prevent tumors from forming with mutations detrimental to growth. To establish the model, N-TVA mice were injected with RCAS H3.3K27M-P2A-PDGFB, RCAS H3.3G34R-P2A-PDGFB, or H3.3WT-P2A-PDGFB. The mean survival of mice injected with H3.3K27M and H3.3S31A was 81 and 68 days, respectively, and 100% of S31A mice developed HGG. In contrast, H3.3WT caused only low-grade tumors in 46% of the mice, and all mice survived until 100 days. In ongoing experiments with H3.3G34R, 23% of mice succumb to tumors by 80 days. These results provide mechanistic insights into the early establishment of pHGGs and established a new mouse model to study the role of histone mutation and PTMs in tumor development.
DIPG-05. HISTONE H3.3 K27M IMPAIRS SER31 PHOSPHORYLATION, RESULTING IN CHROMOSOMAL INSTABILITY, LOSS OF CELL CYCLE CHECKPOINT CONTROL, AND TUMOR FORMATION
Langfald, Alyssa, Grigore, Florina , Fadness, Sela, Sepaniac, Leslie A., Vaughan, Kevin T. , Day, Charles , Stumpff, Jason , Robinson, James, Hinchcliffe, Edward H.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii288-iii288

10.1093/neuonc/noaa222.057 Get It

Abstract Diffuse midline gliomas with the H3.3 K27M mutation are lethal brain tumors in children. H3 K27M causes global loss of Lys27 triple methylation (Lys27me3), inducing epigenetic reprograming. Here we show that H3.3 K27M also causes decreased H3.3 Ser31 phosphorylation on mitotic chromosomes. We show that H3.3 K27M DIPG cells have reduced pericentromeric phospho-Ser31 and increased rates of chromosome missegregation compared to normal, diploid human cells. CRISPR-editing K27M to M27K restored phospho-Ser31 to WT levels and dramatically decreased the rate of chromosome missegregation. We confirm that Chk1 is the H3.3 Ser31 kinase: K27M mutant H3.3 protein exhibits ~60% reduced Chk1 phosphorylation of Ser31 in vitro. Chk1 knockdown completely abolishes phospho-Ser31 in cells and these have increased rates of chromosome missegregation. In normal, diploid cells, expression of K27M or an S31A non-phosphorylatable mutant increased chromosome missegregation; this is suppressed by expressing a phosphomimetic double mutant (K27M/S31E) that restores phospho-Ser31. WT cells arrest following chromosome missegregation. However, cells expressing H3.3 K27M or S31A fail to arrest - despite having WT p53. Finally, we expressed H3F3AS31A and PDGFb in an RCAS/TVA mouse model of DIPG and ~80% developed diffuse high-grade brain tumors and show significantly decreased survival. Our results suggest that loss of phospho-Ser31 alone is oncogenic because H3.3 S31A-expressing cells are WT for K27me3. Our results demonstrate that H3.3 K27M inhibits Ser31 phosphorylation both in vitro and in vivo, leading to both chromosome missegregation and loss of subsequent G1 arrest – thus creating diffuse midline gliomas with both dynamic, complex karyotypes and epigenetic reprogramming.
DIPG-76. HISTONE H3 PHOSPHORYLATION IN H3K27M MIDLINE GLIOMAS
Zhang, Liang , Day, Charles , Hinchcliffe, Edward H. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii302-iii302

10.1093/neuonc/noaa222.118 Get It

Abstract Diffuse midline gliomas (DMG) patients have a dire prognosis despite radiation therapy and there is an urgent need to develop more effective treatments. DMG are characterized by heterozygous mutations in select H3 genes resulting in the replacement of lysine 27 by methionine (K27M) that leads to global epigenetic reprogramming and drives tumorigenesis. We previously reported that pharmacological inhibition of aurora kinase (AKI) may represent a targeted approach for treating tumors with this mutation. Our analysis with both published dataset and patient samples showed that patients with higher aurora kinase A (AKA) expression were associated with worse survival. AKA phosphorylates H3S10 and H3S28 during mitosis. Intriguingly, phosphorylation of the H3S28 (H3S28ph) by AKA blocks PRC2 methyltransferase activity and decreases global H3K27me3 in certain stem cells. We propose that a similar mechanism occurs in H3K27M DMG tumors, where there is a reciprocal relationship between H3S28ph and H3K27me3. We found that AKI significantly decreases H3S28ph while increasing H3K27me3 specifically in H3K27M tumors. To further evaluate the link between the H3K27M mutation and H3 serine phosphorylation, we used CRISPR/Cas9-directed gene editing to silence H3S28ph by replacing serine with alanine (H3S28A) in DIPG cell lines. Ectopic expression of histone H3S28A leads to a prominent epigenetic changes in H3K27M tumors and is similar to AKA inhibition. Overall, this study highlights H3S28ph, one of the targets of AK, is a key driver of epigenetic changes in H3K27M tumors through both direct and indirect changes to H3K27me3 and H3K27ac across the genome.
DIPG-78. REVERTANCE OF THE H3K27M MUTATION RESCUES CHROMATIN MARKS NECESSARY FOR ONCOGENESIS IN DIFFUSE MIDLINE GLIOMA
Zhang, Liang , Nesvick, Cody L. , Day, Charles , Hinchcliffe, Edward H. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii302-iii302

10.1093/neuonc/noaa222.120 Get It

Abstract Diffuse midline glioma (DMG) is a lethal brain tumor that typically occurs in children. Numerous studies have demonstrated the central role of the H3K27M mutation and secondary loss of H3K27 trimethylation (H3K27me3) in DMG tumorigenesis. Understanding how the H3K27M mutation alters the epigenetic landscape of the cell is necessary for revealing molecular targets that are critical to tumorigenesis. To investigate the epigenetic effects of H3K27M mutation in DMG, we developed revertant DMG cell lines with the mutant methionine residue reverted to wildtype (i.e., M27K). Revertant cells were analyzed for epigenetic changes and phenotypic differences in vitro and in vivo. H3M27K DMG cells grew in culture but displayed diminished proliferative capacity. H3M27K cells demonstrated total loss of H3K27M expression and restored trimethylation of H3K27 and H3K4. Furthermore, consistent with the hypothesis that the H3K27M mutation impacts H3 phosphorylation via expression of Aurora Kinase during mitosis, H3M27K cells demonstrated reduced expression of both Aurora Kinase A and phosphorylation of H3 serine residues 10 and 28. In line with the critical role of H3S10 phosphorylation in chromatin segregation, H3M27K cells also demonstrated restored chromosome segregation compared to H3K27M cells. In vivo data will be discussed. Revertance of the H3K27M mutation reduces tumorigenesis in DMG tumors. Isogenic H3M27K cells display reversal of key epigenetic changes associated with oncogenesis in DMG. The revertant H3M27K DMG model is a useful tool to investigate the downstream epigenetic reprogramming specific to H3K27M mutation in these tumors.
Brain volumetric deficits in MAPT mutation carriers: a multisite study
Chu, Stephanie A. , Flagan, Taru , Staffaroni, Adam M. , Jiskoot, Lize C. , Deng, Jersey, Sturm, Virginia E. , Yokoyama, Jennifer S. , Papma, Janne M. , Geschwind, Dan, Rosen, Howard J. , Boxer, Adam L. , Heuer, Hilary W. , Forsberg, Leah K. , Brushaber, Danielle , Coppola, Giovanni , Bordelon, Yvette , Faber, Kelley , Feldman, Howard , Fields, Julie A. , Gavrilova, Ralitza H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Kantarci, Kejal , Kaufer, Daniel , Karydas, Anna M., Kornak, John , Kramer, Joel H. , Kukull, Walter A. , Mackenzie, Ian R. , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Rademakers, Rosa , Ramos, Eliana Marisa , Roberson, Erik D. , Tartaglia, Maria Carmela , Tatton, Nadine , Toga, Arthur W. , Vetor, Ashley, Weıntraub, Sandra , Wong, Bonnie , Lee, Suzee E. , Brushaber, Danielle E, Kantarci, Kejal , Knopman, David S. , Lee, Suzee E , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Pantelyat, Alex , Tartaglia, Maria Carmela , Yokoyama, Jennifer , Feldman, Howard H , Jiskoot, Lize C , Spina, Salvatore , Zhang, Liwen , Seeley, William W. , Boeve, Bradley F. , Grossman, Murray , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Irwin, David J. , Knopman, David S. , Lapid, Maria I. , Litvan, Irene , Wszołek, Zbigniew K. , Swieten, John C. van

Mayo Clinic

Annals of Clinical and Translational Neurology | November 28, 2020 | Volume: 8 | Issue: 1 | Pages: 95-110

10.1002/acn3.51249 | PMID 33247623 Get It

AbstractObjectiveMAPT mutations typically cause behavioral variant frontotemporal dementia with or without parkinsonism. Previous studies have shown that symptomatic MAPT mutation carriers have frontotemporal atrophy, yet studies have shown mixed results as to whether presymptomatic carriers have low gray matter volumes. To elucidate whether presymptomatic carriers have lower structural brain volumes within regions atrophied during the symptomatic phase, we studied a large cohort of MAPT mutation carriers using a voxelwise approach.MethodsWe studied 22 symptomatic carriers (age 54.7 ± 9.1, 13 female) and 43 presymptomatic carriers (age 39.2 ± 10.4, 21 female). Symptomatic carriers’ clinical syndromes included: behavioral variant frontotemporal dementia (18), an amnestic dementia syndrome (2), Parkinson’s disease (1), and mild cognitive impairment (1). We performed voxel‐based morphometry on T1 images and assessed brain volumetrics by clinical subgroup, age, and mutation subtype.ResultsSymptomatic carriers showed gray matter atrophy in bilateral frontotemporal cortex, insula, and striatum, and white matter atrophy in bilateral corpus callosum and uncinate fasciculus. Approximately 20% of presymptomatic carriers had low gray matter volumes in bilateral hippocampus, amygdala, and lateral temporal cortex. Within these regions, low gray matter volumes emerged in a subset of presymptomatic carriers as early as their thirties. Low white matter volumes arose infrequently among presymptomatic carriers.InterpretationA subset of presymptomatic MAPT mutation carriers showed low volumes in mesial temporal lobe, the region ubiquitously atrophied in all symptomatic carriers. With each decade of age, an increasing percentage of presymptomatic carriers showed low mesial temporal volume, suggestive of early neurodegeneration.
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
Winthrop, Kevin , Loftus, Edward V. , Baumgart, Daniel C. , Reinisch, Walter , Nduaka, Chudy I., Lawendy, Nervin, Chan, Gary , Mundayat, Rajiv , Friedman, Gary S. , Salese, Leonardo , Su, Chinyu , Loftus, Edward V , Reinisch, Walter , Thorpe, Andrew J

Mayo Clinic

Journal of Crohn's and Colitis | November 23, 2020 | Volume: 15 | Issue: 6 | Pages: 914-929

10.1093/ecco-jcc/jjaa233 | PMID 33245746 Get It

Abstract Background and Aims Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes. Methods Three cohorts were analysed: Induction [P2/3 induction studies]; Maintenance [P3 maintenance study]; and Overall [all tofacitinib-treated patients in induction, maintenance, or ongoing, open-label, long-term extension studies; as of May 2019]. Proportions and incidence rates [IRs; unique patients with events/100 patient-years] of serious infections [SIs], herpes zoster [HZ] [non-serious and serious], and opportunistic infections [OIs] are reported [censored at time of event]. Results In the Induction Cohort [N = 1220], no patients receiving placebo and eight [0.9%] receiving tofacitinib 10 mg twice daily [BID] developed SIs. Maintenance Cohort [N = 592] SI IRs (95% confidence interval [CI]) were 1.94 [0.23–7.00] for placebo and 1.35 [0.16–4.87] and 0.64 [0.02–3.54] for tofacitinib 5 and 10 mg BID, respectively; HZ IRs were 0.97 [0.02–5.42], 2.05 [0.42–6.00], and 6.64 [3.19–12.22], respectively. In the Overall Cohort [N = 1157; 82.9% predominantly received tofacitinib 10 mg BID], SI, HZ, and non-HZ OI IRs were 1.70 [1.24–2.27], 3.48 [2.79–4.30], and 0.15 [0.04–0.38], respectively. No SIs resulted in death. Conclusions During induction, SIs were more frequent with tofacitinib versus placebo. SIs were generally infrequent in the Maintenance and Overall Cohorts, with rates comparable between treatment groups. Maintenance Cohort HZ IR was numerically higher with tofacitinib 10 mg BID versus 5 mg BID. Overall Cohort HZ IRs remained stable over time. Non-HZ OIs and viral infections were rare.
Abstract 12785: The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse Events
Akar, Joseph G. , Nichols, Sheila, Marcus, Gregory M. , Selzman, Kimberly A. , Varosy, Paul D. , Masoudi, Frederick A. , Du, Chengan, Curtis, Jeptha P. , Kowey, Peter R. , Marcus, Gregory M , Hsu, Jonathan C. , Marine, Joseph Edward , Natale, Andrea , Noseworthy, Peter A. , Freeman, James V.

Mayo Clinic

Circulation | November 12, 2020 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.12785 Get It

Introduction: The American College of Cardiology developed the National Cardiovascular Data Registry (NCDR) AFib Ablation Registry to assess prevalence, demographics, procedural management and outcomes of patients undergoing atrial fibrillation (AFib) ablation procedures. The objective of this registry’s first presentation is to summarize initial AFib Ablation Registry data regarding patient characteristics, procedural characteristics, and in-hospital adverse events and outcomes in those undergoing AFib ablation enrolled in the registry. Methods: Data were tabulated and summarized with simple proportions for categorical data, and mean ± standard deviation for continuous data. Results: A total of 31,345 patients who underwent AFib ablation were included in the registry (mean age 65.0 ± 10.4, 65.2% male, 57.6% paroxysmal AFib), with ablations performed at 120 hospitals, by 501 physicians. The mean CHA2DS2-VASc score of was 2.6 ± 1.6, and mean HAS-BLED score was 1.1 ± 0.9. Successful pulmonary vein isolation was able to be achieved in all veins in 94.5% of patients. The prevalence of any complication during procedural admission was 3.1%; the most common were hematoma (0.5%) and pericardial effusion requiring intervention (0.42%). The mean length of stay during the index admission (days) was 1.4 ± 7.6, and in-hospital death prevalence was 0.04% [FIGURE] . Conclusions: In conclusion, the NCDR AFib Ablation Registry is a large, national, multi-center, prospective cohort study to describe events outside the clinical trial or research setting, demonstrating successful pulmonary vein isolation in the majority of patients and a low prevalence of adverse events. Future studies from the registry will be able to help support and develop evidence-based guidelines for AFib ablation treatment and optimize patient outcomes.
Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions
Morris, Alan H. , Orme, James F., Clemmer, Terry P., Weaver, Lindell K., Thomas, Frank, Grissom, Colin K. , Hirshberg, Ellie , East, Thomas D. , Wallace, C. Jane, Young, Michael , Sittig, Dean F. , Bombino, Michela, Beck, Eduardo, Sward, Katherine , Phansalkar, Shobha, Bernard, Gordon R. , Brower, Roy G., Truwit, Jonathon D. , Steingrub, Jay, Willson, Douglas F., Randolph, Adrienne G. , Curley, Martha A. Q. , Newth, Christopher J. L. , Lacroix, Jacques, Agus, Michael S. D. , Lee, Kang H., deBoisblanc, Bennett P., Evans, R. Scott, Sorenson, Dean, Wong, Anthony, Boland, Michael V. , Grainger, David W. , Dere, W. , Crandall, Alan S. , Huff, Stanley M. , Haug, Peter J. , Pielmeier, Ulrike , Rees, Stephen Edward , Karbing, Dan Stieper , Goldring, Roberta M. , Berger, Kenneth I. , Oppenheimer, Beno W. , Pickering, Brian W. , Schoenfeld, David , Tocino, Irena , Savitz, Lucy A., Dreyfuss, Didier, Slutsky, Arthur S. , Crapo, James D. , Pinsky, Michael R. , James, Brent C., Berwick, Donald M. , Sittig, Dean F , Weir, Charlene , Randolph, Adrienne G , Sward, Katherine A , Stagg, Brian C. , Lanspa, Michael J. , Pesenti, Antonio Maria , Thompson, Bruce , Hite, R. Duncan , Zimmerman, Jerry J. , Nadkarni, Vinay , Facelli, Julio Cesar , Andreassen, Steen , Fan, Eddy , Ely, Eugene Wesley , Gajic, Ognjen , Gonnering, Russell S , Pronovost, Peter J. , Angus, Derek C.

Mayo Clinic

Journal of the American Medical Informatics Association | November 11, 2020 | Volume: 28 | Issue: 6 | Pages: 1330-1344

10.1093/jamia/ocaa294 | PMID 33594410 Get It

AbstractClinical decision-making is based on knowledge, expertise, and authority, with clinicians approving almost every intervention—the starting point for delivery of “All the right care, but only the right care,” an unachieved healthcare quality improvement goal. Unaided clinicians suffer from human cognitive limitations and biases when decisions are based only on their training, expertise, and experience. Electronic health records (EHRs) could improve healthcare with robust decision-support tools that reduce unwarranted variation of clinician decisions and actions. Current EHRs, focused on results review, documentation, and accounting, are awkward, time-consuming, and contribute to clinician stress and burnout. Decision-support tools could reduce clinician burden and enable replicable clinician decisions and actions that personalize patient care. Most current clinical decision-support tools or aids lack detail and neither reduce burden nor enable replicable actions. Clinicians must provide subjective interpretation and missing logic, thus introducing personal biases and mindless, unwarranted, variation from evidence-based practice. Replicability occurs when different clinicians, with the same patient information and context, come to the same decision and action. We propose a feasible subset of therapeutic decision-support tools based on credible clinical outcome evidence: computer protocols leading to replicable clinician actions (eActions). eActions enable different clinicians to make consistent decisions and actions when faced with the same patient input data. eActions embrace good everyday decision-making informed by evidence, experience, EHR data, and individual patient status. eActions can reduce unwarranted variation, increase quality of clinical care and research, reduce EHR noise, and could enable a learning healthcare system.
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos, Guilherme Piovezani , Dimopoulos, Christina , McDonald, Nicholas , Janssens, Laurens , Hung, Kenneth W, Proctor, Deborah D., Ruggiero, Elizabeth, Kane, Sunanda V. , Bruining, David H. , Faubion, William A. , Raffals, Laura E. , Loftus, Edward V. , Al‐Bawardy, Badr , McDonald, Nicholas M, Janssens, Laurens P, Loftus, Edward V , Ramos, Guilherme P , Janssens, Laurens P , Hung, Kenneth W

Mayo Clinic

Inflammatory Bowel Diseases | November 9, 2020 | Volume: 27 | Issue: 8 | Pages: 1270-1276

10.1093/ibd/izaa293 | PMID 33165569 Get It

Abstract Background There are limited data on how vedolizumab (VDZ) impacts extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). The aim of this study was to determine the clinical outcomes of EIMs after initiation of VDZ for patients with IBD. Methods A multicenter retrospective study of patients with IBD who received at least 1 dose of VDZ between January 1, 2014 and August 1, 2019 was conducted. The primary outcome was the rate of worsening EIMs after VDZ. Secondary outcomes were factors associated with worsening EIMs and peripheral arthritis (PA) specifically after VDZ. Results A total of 201 patients with IBD (72.6% with Crohn disease; median age 38.4 years (interquartile range, 29-52.4 years); 62.2% female) with EIMs before VDZ treatment were included. The most common type of EIM before VDZ was peripheral arthritis (PA) (68.2%). Worsening of EIMs after VDZ occurred in 34.8% of patients. There were no statistically significant differences between the worsened EIM (n = 70) and the stable EIM (n = 131) groups in term of age, IBD subtype, or previous and current medical therapy. We found that PA was significantly more common in the worsening EIM group (84.3% vs 59.6%; P < 0.01). Worsening of EIMs was associated with a higher rate of discontinuation of VDZ during study follow-up when compared with the stable EIM group (61.4% vs 44%; P = 0.02). Treatment using VDZ was discontinued specifically because of EIMs in 9.5% of patients. Conclusions Almost one-third of patients had worsening EIMs after VDZ, which resulted in VDZ discontinuation in approximately 10% of patients. Previous biologic use or concurrent immunosuppressant or corticosteroid therapy did not predict EIM course after VDZ.